{"id":"NCT01681992","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life","officialTitle":"Immunogenicity and Safety Study of GSK Biologicals' Priorix Vaccine (209762) at an End of Shelf-life Potency Compared to Merck & Co., Inc.'s Measles-mumps-rubella (MMR) Vaccine When Both Are Given on a 2-dose Schedule to Healthy Children in Their 2nd Year of Life","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10-10","primaryCompletion":"2015-02-03","completion":"2015-08-18","firstPosted":"2012-09-10","resultsPosted":"2018-08-17","lastUpdate":"2021-01-07"},"enrollment":4538,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Measles","Mumps","Rubella","Measles-Mumps-Rubella Vaccine"],"interventions":[{"type":"BIOLOGICAL","name":"Priorix","otherNames":["GSK Biologicals' live attenuated measles","mumps","rubella vaccine"]},{"type":"BIOLOGICAL","name":"M-M-R II","otherNames":["Merck & Co.","Inc.'s measles","mumps","rubella virus vaccine","live"]},{"type":"BIOLOGICAL","name":"Varivax","otherNames":["Merck & Co.","Inc.'s varicella virus vaccine","live"]},{"type":"BIOLOGICAL","name":"Havrix","otherNames":["GSK Biologicals' hepatitis A vaccine","inactivated"]},{"type":"BIOLOGICAL","name":"Prevnar 13","otherNames":["Pfizer Inc.'s pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein)"]}],"arms":[{"label":"Inv_MMR_Min Group","type":"EXPERIMENTAL"},{"label":"Inv_MMR_Med Group","type":"EXPERIMENTAL"},{"label":"Com_MMR Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate end of shelf-life potency in terms of the immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to Merck \\& Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).","primaryOutcome":{"measure":"Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value (by Enzyme-linked Immunosorbent Assay [ELISA])","timeFrame":"At Day 42","effectByArm":[{"arm":"Inv_MMR_Min Group","deltaMin":90.9,"sd":null},{"arm":"Inv_MMR_Med Group","deltaMin":94.3,"sd":null},{"arm":"Com_MMR Group","deltaMin":96.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":15},"locations":{"siteCount":81,"countries":["United States","Czechia","Finland","Malaysia","Puerto Rico","Spain","Thailand"]},"refs":{"pmids":["30104117"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":91,"n":1493},"commonTop":["Irritability","Decreased appetite","Somnolence","Upper respiratory tract infection","Pain"]}}